Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion

Guang-Yun SongDivision of Translational Vaccine Research, and Division of General and Oncologic Surgery, City of Hope National Medical Center, Duarte, California, USA

Tumul SrivastavaDivision of Translational Vaccine Research, and Division of General and Oncologic Surgery, City of Hope National Medical Center, Duarte, California, USA

Hidenobu IshizakiDivision of Translational Vaccine Research, and Division of General and Oncologic Surgery, City of Hope National Medical Center, Duarte, California, USA

Simon F. LaceyDivision of Translational Vaccine Research, and Division of General and Oncologic Surgery, City of Hope National Medical Center, Duarte, California, USA

Don J. DiamondDivision of Translational Vaccine Research, and Division of General and Oncologic Surgery, City of Hope National Medical Center, Duarte, California, USA

Joshua D. I. EllenhornDivision of Translational Vaccine Research, and Division of General and Oncologic Surgery, City of Hope National Medical Center, Duarte, California, USACorrespondence[email protected]

Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date